Abuse Liability of Intravenous Buprenorphine/Naloxone and Buprenorphine Alone in Buprenorphine-Maintained Intravenous Heroin Abusers

Addiction - United Kingdom
doi 10.1111/j.1360-0443.2009.02843.x
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Buprenorphine–naloxone

CMAJ
Medicine
2018English

Enzymatic Assay for Urine Lactose in Assessment of Recent Intravenous Abuse of Buprenorphine

Drug Testing and Analysis
Environmental ChemistryAnalytical ChemistrySpectroscopyPharmaceutical Science
2019English

Comparative Pharmacokinetics of Intravenous Fentanyl and Buprenorphine in Healthy Greyhound Dogs

Journal of Veterinary Pharmacology and Therapeutics
VeterinaryPharmacology
2014English

Buprenorphine/Naloxone Maintenance Therapy in Patients With Meperidine Use Disorder

International Journal of Basic & Clinical Pharmacology
2017English

Pharmacokinetic Interactions Between Buprenorphine/Naloxone and Once-Daily Lopinavir/Ritonavir

Journal of Acquired Immune Deficiency Syndromes
Infectious DiseasesPharmacology
2010English

Maternal Buprenorphine Dose, Placenta Buprenorphine, and Metabolite Concentrations and Neonatal Outcomes

Therapeutic Drug Monitoring
Pharmacology
2010English

Sustained Release D-Amphetamine Reduces Cocaine but Not ‘Speedball’-Seeking in Buprenorphine-Maintained Volunteers: A Test of Dual-Agonist Pharmacotherapy for Cocaine/Heroin Polydrug Abusers

Neuropsychopharmacology
PsychiatryMental HealthPharmacology
2010English

Prior Buprenorphine Experience Is Associated With Office-Based Buprenorphine Treatment Outcomes

Journal of Addiction Medicine
PsychiatryMental HealthPharmacology
2013English

Should the United States Government Repeal Restrictions on Buprenorphine/Naloxone Treatment?

Substance Use and Misuse
Mental HealthEnvironmentalPublic HealthPsychiatryHealthMedicineOccupational Health
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy